Skip to main content

Table 2 Comparison between the patient group (pre-TMS) and control group as regards neurokinin A serum level, and comparison between pre-TMS and post-TMS treatment neurokinin A serum level in the patient group

From: Repetitive transcranial magnetic stimulation as a prophylactic treatment in migraine

Neurokinin A serum level Control group, no. = 20 Patient group, no. = 40 Test value P value
Pre-TMS Mean ± SD 1.15 ± 0.28* 24.11 ± 2.26 − 45.131 < 0.001
Range 0.51–1.85 19.38–27.93
Post-TMS in patient group Mean ± SD 1.15 ± 0.28* 12.60 ± 3.08 − 16.524 < 0.001
Range 0.51–1.85 9.32–25.45
Paired t test   − 5.511   
P value   < 0.001 (HS)
  1. P value > 0.05, non-significant (NS); P value < 0.05, significant (S); P value < 0.01, highly significant (HS)
  2. Independent t test
  3. *Neurokinin A serum level was calculated in the control group one time used in the comparison with the patient group serum level pre-TMS and post-TMS